Unfortunately, while outcomes for patients with CML improved greatly with the development of BCR::ABL1 TKIs, CML-related deaths due to progression from chronic to advanced disease occur in up to 15% of patients with limited therapy options depending on clinical factors present at diagnosis and types of TKI treatment [3–5]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.